Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis

[1]  N. Syn,et al.  Chemotherapy for advanced gastric cancer. , 2017, The Cochrane database of systematic reviews.

[2]  X. Qin,et al.  The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III , 2017, BMC Cancer.

[3]  P. Schirmacher,et al.  Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multice , 2016, The Lancet. Oncology.

[4]  Yuan Ji,et al.  Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX) , 2016, Oncotarget.

[5]  Yuan Ji,et al.  Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: Capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). , 2016 .

[6]  A. Nashimoto,et al.  Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer , 2016, International Journal of Clinical Oncology.

[7]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[8]  B. Xiong,et al.  Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: an updated meta-analysis of randomized controlled trials. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  N. Zengi̇n,et al.  Erratum to: Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study , 2014, Cancer Chemotherapy and Pharmacology.

[10]  N. Zengi̇n,et al.  Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: A phase II NEOTAX study. , 2014 .

[11]  T. Yoshikawa,et al.  Accuracy of CT Staging of Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy: Cohort Evaluation within a Randomized Phase II Study , 2014, Annals of Surgical Oncology.

[12]  G. Lee,et al.  A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma , 2013, Cancer Chemotherapy and Pharmacology.

[13]  C. Bokemeyer,et al.  The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). , 2013, European journal of cancer.

[14]  Junji Kato,et al.  A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker , 2013, Cancer Chemotherapy and Pharmacology.

[15]  Y. Kodera,et al.  Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry , 2012, Gastric Cancer.

[16]  S. Al-Batran,et al.  Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer , 2012, British Journal of Cancer.

[17]  J. Pignon,et al.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[19]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[20]  N. Zengi̇n,et al.  Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study , 2014, Cancer Chemotherapy and Pharmacology.

[21]  T. Yoshikawa,et al.  Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial , 2013, Annals of Surgical Oncology.

[22]  Japanese Gastric Cancer Association.  Japanese classification of gastric carcinoma: 3rd English edition , 2011, Gastric Cancer.

[23]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2010 (ver. 3) , 2011, Gastric Cancer.

[24]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[25]  胃癌研究会.  Japanese classification of gastric carcinoma , 1995 .